Nebius Group NV vs Zimmer Biomet Holdings Inc — how do they compare? Nebius Group NV trades at $218.2 (market cap $46.37B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Nebius Group NV is far larger — about 2.7× Zimmer Biomet Holdings Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.07% dividend while Nebius Group NV pays none. Which is the better fit depends on your goals.
| NBIS | ZBH | |
|---|---|---|
Market Cap | $46.37B | $17.36B |
Sector | Technology | Health |
52-Week High | $286.69 | $107.71 |
52-Week Low | $50.40 | $79.58 |
Enterprise Value | $46.56B | $24.40B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
NBIS stock surged 22.06% to $216.92 on July 21, 2026, driven by NVIDIA's disclosure of a 9.3% stake, signaling strong AI cloud partnership potential. Despite a bearish technical signal, the company shows robust revenue growth projections, with 2026 net income margin expected at 93.08%. Recent earnings beat expectations in two of the last three quarters, though cash flow trends highlight significant investing outflows.
The outlook is bullish based on analyst consensus and strategic alliances, but risks include high valuation multiples and competitive pressures from tech giants. Investment opportunity centers on AI infrastructure demand, while caution is advised due to volatility and execution risks in scaling operations.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →